Racura Oncology (RAC) Q3 2026 TU earnings summary

Executive summary

• Developed a new blood-based molecular test to evaluate cardioprotective effects of RC220 in the CPACS Phase 1 trial.

• Initiated collaboration with Emory University to study (E,E)-bisantrene in osimertinib-resistant EGFRm NSCLC models.

• First patient recruited to Phase 1 HARNESS-1 clinical trial for NSCLC with EGFR mutations.

• Presented findings on (E,E)-bisantrene's MYC gene silencing at AACR 2026 Annual Meeting.

• Held inaugural R&D Symposium, outlining clinical programs and commercial strategy.

Financial highlights

• Cash and cash equivalents at 31 March 2026 totaled $19.38 million.

• 81% of quarterly spending ($2.44m) directed to R&D and drug manufacturing.

• Net cash used in operating activities for the quarter was $(3.01)m; for nine months, $(5.20)m.

• Early conversion of options provided $1.44m in additional funding.

• Estimated 6.45 quarters of funding available at current burn rate.

Outlook and guidance

• Current cash position expected to fund all committed activities through calendar year 2027.

• Ongoing focus on advancing clinical trials and exploring partnerships or M&A to accelerate RC220 access.